Curcumin reduces cytotoxicity of 5-fluorouracil treatment in human breast cancer cells

Journal of Medicinal Food

Volumn 18, Issue 4, 2015, Pages 497-502

  Ferguson, Jeannette E ^a   Orlando, Robert A ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

5 fluorouracil; 5 FU; curcumin; cytotoxicity; MDA MB 231

Indexed keywords

CURCUMIN; FLUOROURACIL; OXIDOREDUCTASE; TETRAZOLIUM;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BRDU ASSAY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CELL PROLIFERATION; CELL VIABILITY; CELL VIABILITY ASSAY; CYTOTOXICITY; DNA SYNTHESIS; DRUG POTENCY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; LD 50; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT RESPONSE; BREAST NEOPLASMS; CELL SURVIVAL; DRUG EFFECTS; PATHOPHYSIOLOGY; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CURCUMIN; FEMALE; FLUOROURACIL; HUMANS;

EID: 84926482434     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2013.0086     Document Type: Article

References (53)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Zhou Y, Eppenberger-Castori S, Eppenberger U, Benz CC: The NFkappaB pathway and endocrine-resistant breast cancer. En-docr Relat Cancer 2005;12 Suppl 1:S37-S46.
3. Osborne CK, Fuqua SA: Mechanisms of tamoxifen resistance. Breast Cancer Res Treat 1994;32:49-55.
4. Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN: Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 2001;6:133-146.
5. Cameron DA, Gabra H, Leonard RC: Continuous 5-fluorouracil in the treatment of breast cancer. Br J Cancer 1994;70:120-124.
6. Curreri AR, Ansfield FJ, Mc IF, Waisman HA, Heidelberger C: Clinical studies with 5-fluorouracil. Cancer Res 1958;18:478-484.
7. Bonnadonna G, Valagussa P: Systemic therapy in resectable breast cancer. In: Hematology/Oncology Clinics of North Amer ica: Diagnosis and Therapy of Breast Cancer (Henderson IE, ed.). W.B. Saunders, Philadelphia, 1989, pp. 727-742.
8. Ansfield FJ, Ramirez G, Mackman S, Bryan GT, Curreri AR: A ten-year study of 5-flurouracil in disseminated breast cancer with clinical results and survival times. Cancer Res 1969;29:1062-1066.
9. Johnson MD, Kenney N, Stoica A, et al.: Cadmium mimics the in vivo effects of estrogen in the uterus and mammary gland. Nat Med 2003;9:1081-1084.
10. Marchal JA, Rodriguez-Serrano F, Caba O, et al.: Anti-proliferative activity, cell-cycle dysregulation, and cellular dif ferentiation: salicyl-and catechol-derived acyclic 5-fluorouracil O, N-acetals against breast cancer cells. Chem Med Chem 2007;2:1814-1821.
11. Carter SK: Integration of chemotherapy into combined modality treatment of solid tumors VII. Adenocarcinoma of the breast. Cancer Treat Rev 1976;3:141-174.
12. Bocci G, Danesi R, Di Paolo AD, et al.: Comparative pharma-cokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5, 6-dihydrouracil after conventional and reduced test dose in cancer patients. Clin Cancer Res 2000;6:3032-3037.
13. Peters GJ: Antimetabolites. In: Oxford Textbook of Oncology (Peckam M, Pinedo HM, Veronesi U, eds.). Oxford University Press, London, 1995, pp. 524-552.
14. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol 1998;16: 301-308.
15. Longley DB, Harkin DP, Johnston PG: 5-fluorouracil: mecha nisms of action and clinical strategies. Nat Rev Cancer 2003;3: 330-338.
16. Amstutz U, Froehlich TK, Largiader CR: Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics 2011;12:1321-1336.
17. Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB: Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol 2006;69:195-206.
18. Du B, Jiang L, Xia Q, Zhong L: Synergistic inhibitory effects of curcumin and 5-fluorouracil on the growth of the human colon cancer cell line HT-29. Chemotherapy 2006;52:23-28.
19. Dorai T, Cao YC, Dorai B, Buttyan R, Katz AE: Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogen-esis of LNCaP prostate cancer cells in vivo. Prostate 2001;47: 293-303.
20. Koo JY, Kim HJ, Jung KO, Park KY: Curcumin inhibits the growth of AGS human gastric carcinoma cells in vitro and shows synergism with 5-fluorouracil. J Med Food 2004;7:117-121.
21. Tian F, Fan T, Zhang Y, Jiang Y, Zhang X: Curcumin potentiates the antitumor effects of 5-FU in treatment of esophageal squa-mous carcinoma cells through downregulating the activation of NF-kappaB signaling pathway in vitro and in vivo. Acta Biochim Biophys Sin (Shanghai) 2012;44:847-855.
22. Speciale A, Chirafisi J, Saija A, Cimino F: Nutritional antioxi-dants and adaptive cell responses: an update. Curr Mol Med 2011;11:770-789.
23. Sung B, Prasad S, Yadav VR, Aggarwal BB: Cancer cell sig naling pathways targeted by spice-derived nutraceuticals. Nutr Cancer 2012;64:173-197.
24. Bocci G, Barbara C, Vannozzi F, et al.: A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. Clin Pharmacol Ther 2006;80:384-395.
25. van Kuilenburg AB, Meinsma R, van Gennip AH: Pyrimidine degradation defects and severe 5-fluorouracil toxicity. Nucleo-sides Nucleotides Nucleic Acids 2004;23:1371-1375.
26. Douillard JY, Cunningham D, Roth AD, et al.: Irinotecan com bined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-1047.
27. Giacchetti S, Perpoint B, Zidani R, et al.: Phase III multicen-ter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic co-lorectal cancer. J Clin Oncol 2000;18:136-147.
28. Aggarwal BB, Shishodia S, Takada Y, et al.: Curcumin sup presses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 2005;11:7490-7498.
29. Choudhuri T, Pal S, Das T, Sa G: Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem 2005;280: 20059-20068.
30. Lin JK, Pan MH, Lin-Shiau SY: Recent studies on the biofunc-tions and biotransformations of curcumin. Biofactors 2000;13: 153-158.
31. Gafner S, Lee SK, Cuendet M, et al.: Biologic evaluation of curcumin and structural derivatives in cancer chemoprevention model systems. Phytochemistry 2004;65:2849-2859.
32. Leu TH, Maa MC: The molecular mechanisms for the anti-tumorigenic effect of curcumin. Curr Med Chem Anticancer Agents 2002;2:357-370.
33. Okazaki Y, Iqbal M, Okada S: Suppressive effects of dietary curcumin on the increased activity of renal ornithine decarbox-ylase in mice treated with a renal carcinogen, ferric nitrilo-triacetate. Biochim Biophys Acta 2005;1740:357-366.
34. Dikshit P, Goswami A, Mishra A, Chatterjee M, Jana NR: Cur-cumin induces stress response, neurite outgrowth and prevent NF-kappaB activation by inhibiting the proteasome function. Neurotox Res 2006;9:29-37.
35. Lee J, Im YH, Jung HH, et al.: Curcumin inhibits interferon-alpha induced NF-kappaB and COX-2 in human A549 non-small cell lung cancer cells. Biochem Biophys Res Commun 2005;334:313-318.
36. Cho JW, Park K, Kweon GR, et al.: Curcumin inhibits the ex pression of COX-2 in UVB-irradiated human keratinocytes (HaCaT) by inhibiting activation of AP-1: p38 MAP kinase and JNK as potential upstream targets. Exp Mol Med 2005;37:186-192.
37. Woo MS, Jung SH, Kim SY, et al.: Curcumin suppresses phorbol ester-induced matrix metalloproteinase-9 expression by inhibit ing the PKC to MAPK signaling pathways in human astroglioma cells. Biochem Biophys Res Commun 2005;335:1017-1025.
38. Mankan AK, Lawless MW, Gray SG, Kelleher D, McManus R: NF-kappaB regulation: the nuclear response. J Cell Mol Med 2009;13:631-643.
39. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr.: NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 1999;19: 5785-5799.
40. Garg AK, Hortobagyi GN, Aggarwal BB, Sahin AA, Buchholz TA: Nuclear factor-kappa B as a predictor of treatment response in breast cancer. Curr Opin Oncol 2003;15:405-411.
41. Haffner MC, Berlato C, Doppler W: Exploiting our knowledge of NF-kappaB signaling for the treatment of mammary cancer. J Mammary Gland Biol Neoplasia 2006;11:63-73.
42. Sorrentino MF, Kim J, Foderaro AE, Truesdell AG: 5-fluoro-uracil induced cardiotoxicity: review of the literature. Cardiol J 2012;19:453-458.
43. Kosmas C, Kallistratos MS, Kopterides P, et al.: Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 2008;134:75-82.
44. Labianca R, Beretta G, Clerici M, Fraschini P, Luporini G: Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tu-mori 1982;68:505-510.
45. Meyer CC, Calis KA, Burke LB, Walawander CA, Grasela TH: Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy 1997;17:729-736.
46. Ezzeldin H, Diasio R: Dihydropyrimidine dehydrogenase defi ciency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer 2004;4:181-189.
47. van Kuilenburg AB, Maring JG, Schalhorn A, et al.: Pharma-cokinetics of 5-fluorouracil in patients heterozygous for the IVS14 + 1G > A mutation in the dihydropyrimidine dehydrogenase gene. Nucleosides Nucleotides Nucleic Acids 2008;27:692-698.
48. Lu Z, Zhang R, Diasio RB: Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993;53:5433-5438.
49. Milano G, McLeod HL: Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment? Eur J Cancer 2000;36:37-42.
50. van Kuilenburg AB, Haasjes J, Richel DJ, et al.: Clinical im plications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identi fication of new mutations in the DPD gene. Clin Cancer Res 2000;6:4705-4712.
51. Saif MW, Choma A, Salamone SJ, Chu E: Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst 2009;101: 1543-1552.
52. Yang CG, Ciccolini J, Blesius A, et al.: DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity. Cancer Chemother Pharmacol 2011;67:49-56.
53. Goel A, Aggarwal BB: Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer 2010;62:919-930.